Literature DB >> 25589457

Inhalation devices and patient interface: human factors.

Stefan Leiner1, David Parkins, Orest Lastow.   

Abstract

The development of any inhalation product that does not consider the patient needs will fail. The needs of the patients must be identified and aligned with engineering options and physical laws to achieve a robust and intuitive-to-use inhaler. A close interaction between development disciplines and real-use evaluations in clinical studies or in human factor studies is suggested. The same holds true when a marketed product needs to be changed. Caution is warranted if an inhaler change leads to a change in the way the patient handles the device. Finally, the article points out potential problems if many inhaler designs are available. Do they confuse the patients? Can patients recall the correct handling of each inhaler they use? How large is the risk that different inhaler designs pose to the public health? The presentations were given at the Orlando Inhalation Conference: Approaches in International Regulation co-organised by the University of Florida and the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) in March 2014.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25589457      PMCID: PMC4365080          DOI: 10.1208/s12248-015-9717-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  11 in total

1.  Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults.

Authors:  Andrea S Melani; Doriana Zanchetta; Natalino Barbato; Piersante Sestini; Cristina Cinti; Piero Aldo Canessa; Stefano Aiolfi; Margherita Neri
Journal:  Ann Allergy Asthma Immunol       Date:  2004-11       Impact factor: 6.347

2.  Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.

Authors:  Wallace P Adams; Richard C Ahrens; Mei-Ling Chen; David Christopher; Badrul A Chowdhury; Dale P Conner; Richard Dalby; Kevin Fitzgerald; Leslie Hendeles; Anthony J Hickey; Günther Hochhaus; Beth L Laube; Paul Lucas; Sau L Lee; Svetlana Lyapustina; Bing Li; Dennis O'Connor; Neil Parikh; David A Parkins; Prasad Peri; Gary R Pitcairn; Michael Riebe; Partha Roy; Tushar Shah; Gur Jai Pal Singh; Sandra Suarez Sharp; Julie D Suman; Marjolein Weda; Janet Woodcock; Lawrence Yu
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-02       Impact factor: 2.849

3.  Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.

Authors:  Bo Olsson; Lars Borgström; Hans Lundbäck; Mårten Svensson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-02-19       Impact factor: 2.849

Review 4.  Orally inhaled drug performance testing for product development, registration, and quality control.

Authors:  Orest Lastow; Mårten Svensson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-12       Impact factor: 2.849

5.  Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease.

Authors:  P K Burnell; T Small; S Doig; B Johal; R Jenkins; G J Gibson
Journal:  Respir Med       Date:  2001-05       Impact factor: 3.415

6.  A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers.

Authors:  B J Gabrio; S W Stein; D J Velasquez
Journal:  Int J Pharm       Date:  1999-09-10       Impact factor: 5.875

7.  Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD.

Authors:  Martina Schulte; Karim Osseiran; Reiner Betz; Marion Wencker; Peter Brand; Thomas Meyer; Peter Haidl
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2008-12       Impact factor: 2.849

8.  Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers.

Authors:  Basheer Y Khassawneh; Musa K Al-Ali; Karem H Alzoubi; Morad Z Batarseh; Saafan A Al-Safi; Abdelmonem M Sharara; Hatem M Alnasr
Journal:  Respir Care       Date:  2008-03       Impact factor: 2.258

9.  Determination of the minimum dose of lactose drug carrier that can be sensed during inhalation.

Authors:  M A Higham; A M Sharara; R P Magee; P W Ind
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

10.  Dry powder inhalers: which factors determine the frequency of handling errors?

Authors:  Siegfried Wieshammer; Jens Dreyhaupt
Journal:  Respiration       Date:  2007-10-02       Impact factor: 3.580

View more
  3 in total

1.  Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.

Authors:  Guenther Hochhaus; Craig Davis-Cutting; Martin Oliver; Sau L Lee; Svetlana Lyapustina
Journal:  AAPS J       Date:  2015-06-02       Impact factor: 4.009

2.  The Repeatability of Inspiration Performance Through Different Inhalers in Patients with Chronic Obstructive Pulmonary Disease and Control Volunteers.

Authors:  Tamas Erdelyi; Zsofia Lazar; Balazs Odler; Lilla Tamasi; Veronika Müller
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2020-05-28       Impact factor: 2.849

3.  Predictors of correct technique in patients using pressurized metered dose inhalers.

Authors:  Kyra Bartolo; Martin Balzan; Emma Louise Schembri; Rachelle Asciak; Darlene Mercieca Balbi; Michael Pace Bardon; Stephen Montefort
Journal:  BMC Pulm Med       Date:  2017-02-28       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.